Search Result
Results for "
Radionuclide
" in MedChemExpress (MCE) Product Catalog:
46
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-106033
-
|
DOTATOC; SDZ-SMT 487; SMT 487
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer . Edotreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-106244
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-106244A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-160131
-
|
|
Others
|
Cancer
|
|
Macropa is a macrocyclic chelator that can be used as radionuclides to study soft tissue metastases .
|
-
-
- HY-P3441A
-
|
|
FAP
|
Cancer
|
|
3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 TFA is often coupled with radionuclides for tumor diagnosis and research .
|
-
-
- HY-147057
-
|
|
FAP
|
Cancer
|
|
FAP-2286 is a potent and selective FAP-binding peptide coupled to a radionuclide chelator with a mean IC50 value of 2.7 nM for binding to FAP. FAP-2286 can chelate radionuclides for imaging or therapeutic applications and has a strong effect on FAP-positive tumors. FAP-2286 can be used for FAP-positive tumor research .
|
-
-
- HY-114377
-
|
|
Others
|
Cancer
|
|
p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .
|
-
-
- HY-139564
-
-
-
- HY-P3441
-
|
|
FAP
|
Cancer
|
|
3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research .
|
-
-
- HY-W283556
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
DO2A-tert-butyl ester is a bifunctional chelator (BFC) that can be used for the coupling of peptides and radionuclides. DO2A-tert-butyl ester can be used in the development of radionuclide imaging tracers .
|
-
-
- HY-148761
-
|
|
PSMA
|
Cancer
|
|
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
|
-
-
- HY-164589
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164653
-
|
|
Others
|
Cancer
|
|
DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164590
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164599
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-P10730
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-P10731
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164592
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DTPA-tetra(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164594
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-P10732
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-W999782
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-P10729
-
|
|
Others
|
Cancer
|
|
DOTA-Bombesin (1-14) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164603
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
3p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164604
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
3p-C-DEPA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164606
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
3p-C-NETA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164596
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164654
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-W999766
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
|
-
-
- HY-W586475
-
|
|
Others
|
Cancer
|
|
Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164591
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
THP(Bz)3-NH2 is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164601
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
3p-C-DE4TA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164602
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
3p-C-NE3TA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-159768A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .
|
-
-
- HY-164593
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-159767A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
(S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .
|
-
-
- HY-P10743
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-164656
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-164588
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
|
-
-
- HY-159770A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
(S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .
|
-
-
- HY-W873634
-
|
TRAP-Pr
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
|
-
-
- HY-164379
-
|
|
Others
|
Cancer
|
|
DOTA-PEG4-alkyne is a linker, and can be used for the labeling of radionuclide .
|
-
-
- HY-P10131
-
|
|
Radionuclide-Drug Conjugates (RDCs)
FAP
|
Cancer
|
|
3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment . 3BP-3940 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
-
- HY-132989
-
-
-
- HY-W011118
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
|
-
-
- HY-160092A
-
|
|
HDAC
|
Neurological Disease
|
|
Martinostat hydrochloride is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .
|
-
-
- HY-160092
-
|
|
HDAC
|
Neurological Disease
|
|
Martinostat is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .
|
-
-
- HY-138134
-
-
-
- HY-134418A
-
-
-
- HY-138269A
-
|
CHX-A''-DTPA-NCS hydrochloride
|
Biochemical Assay Reagents
|
Others
|
|
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
-
- HY-158067
-
-
- HY-W088413
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782078
-
-
- HY-W678394
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.
|
-
- HY-164574
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.
|
-
- HY-W738256
-
|
MDTPA
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Maleimide-DTPA (MDTPA) is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA is a good material for medical imaging or treatment.
|
-
- HY-P2218
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158072
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717830
-
|
|
Biochemical Assay Reagents
|
Others
|
|
CB-Cyclamis a bifunctional chelator (Bifunctional Chelator; BFC), which is a main chain Cyclen derivative of the macrocyclic ligand tetradecane. CB-Cyclam can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717743
-
-
- HY-W726767
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717782
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Bz-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Bz-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W087027A
-
-
- HY-158077
-
|
(R)-tetraMe-DOTA
|
Biochemical Assay Reagents
|
Others
|
|
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
|
-
- HY-W250844A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W755033
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
NH2-PEG4-DOTA is a bifunctional, DOTA-type metal chelator. NH2-PEG4-DOTA can be conjugated with Dextran for quantitative analysis in the presence of a highly luminescent complex. NH2-PEG4-DOTA can also bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
|
-
- HY-129650
-
|
AV-45
|
Others
|
Others
|
|
Flobetapir (AV-45) may be a well-tolerated imaging agent. Flobetapir synthesizes Florbetapir (18F) that is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18 .
|
-
- HY-164577
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
BCN-DOTA-GA is a cyclooctyne-linked DOTA chelator that can be labeled with radioactive zirconium-89 and used as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells or tissues.
|
-
- HY-P10758
-
-
- HY-147057A
-
|
|
FAP
|
Cancer
|
|
FAP-2286 acetate is the conjugate of a fibroblast activation protein (FAP)-binding peptide. FAP-2286 acetate can be labeled with radionuclides for diagnostic applications. FAP-2286 acetate has antitumor activity .
|
-
- HY-W539916
-
-
- HY-128890A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717779
-
|
|
Biochemical Assay Reagents
|
Others
|
|
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-A0074
-
|
tetra-tBu-DTPA
|
Biochemical Assay Reagents
|
Others
|
|
DTPA-tetra (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. DTPA-tetra (t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717781A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH?-Bn-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782088A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH?-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782087A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-SCN-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-SCN-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782083
-
-
- HY-156038
-
|
|
Biochemical Assay Reagents
|
Others
|
|
(S)-p-SCN-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W749627
-
-
- HY-158068
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Maleimido-mono-amide-DTPA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DTPA (TFA) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W802013
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.
|
-
- HY-P10232
-
|
HYNIC-Tyr3-octreotide
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10761
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Carbonic Anhydrase
|
Cancer
|
|
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130?nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10781
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
PSMA-D5 has a binding affinity for PSMA with Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ 68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([ 68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-111605
-
|
|
Radionuclide-Drug Conjugates (RDCs)
ADC Linker
|
Cancer
|
|
Macropa-NCS can be coupled with antibodies to form tumor-selective carrier molecules, which can be further combined with radionuclides as specific targeting cancer cell carriers, and is a linker-chelating agent in targeted alpha research (TAT) .
|
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-131673A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W451440
-
-
- HY-W717800A
-
-
- HY-P10292
-
-
- HY-156138A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
CB-TE2A (tetrahydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC), which is a TETA derivative of the macrocyclic ligand tetradecane backbone. CB-TE2A (tetrahydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717833
-
-
- HY-P10273
-
-
- HY-111895B
-
|
|
Others
|
Others
|
|
Macropa-NH2 TFA is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases .
|
-
- HY-153549
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Others
|
|
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-W717742
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NO2-Bn-Cyclenis a bifunctional chelator (Bifunctional Chelator; BFC), which is a derivative of the macrocyclic ligand dodecane backbone Cyclen. p-NO2-Bn-Cyclen can be used for conjugation of peptides and radionuclides.
|
-
- HY-48876
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782075
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-164569
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions. For example, NH2 DOTA-GA complexes Gd(III) ions.
|
-
- HY-164575
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
NH2-NODAGA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA can react with diethyl squarate in 0.5M phosphate buffer (room temperature, 2 h, pH 7-7.5) to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
|
-
- HY-W087187
-
|
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
|
-
- HY-P10744
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P3440
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PD-1/PD-L1
|
Cancer
|
|
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .
|
-
- HY-158066
-
-
- HY-158069
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH?-Bn-DTPA-penta (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA-penta (t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W250929
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Maleimido-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W460274
-
|
|
Biochemical Assay Reagents
|
Others
|
|
4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-148646A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH2-CHX-A"-DTPA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH2-CHX-A"-DTPA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.
|
-
- HY-P10012
-
|
GYK-DTPA
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma . Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10273A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Biochemical Assay Reagents
|
Cancer
|
|
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-W749614
-
-
- HY-W749603
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782081
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-SCN-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-SCN-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
|
-
- HY-153550
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Others
|
|
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging . PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-W241345
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTA-bis(tert-butyl)ester is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide conjugates (RDCs). DOTA-bis(tert-butyl)ester can be conjugated with different salts to form different metal chelators, such as (HY-B1244) hydrochloride to obtain DOTA-MN2. DOTA-MN2 can be reacted with [67]Ga-citrate to obtain radiolabeling. When (67)Ga-DOTA-MN2 is incubated in phosphate buffer solution or mouse plasma for 24 hours, it does not undergo significant decomposition. In the biodistribution experiment of NFSa tumor mice, it has high tumor uptake and rapid plasma clearance, and is a good material for SPECT and PET studies.
|
-
- HY-160059
-
|
|
Fluorescent Dye
|
Cancer
|
|
JHIT2e aptamer sodium is a molecular probe based on the aptamer JHIT2 of human liver cancer cell line HepG2 cells. JHIT2e aptamer sodiu retains the ability to specifically bind HepG2 and can deliver fluorescent materials or radionuclides to tumors .
|
-
- HY-111895A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
ADC Linker
Drug Intermediate
|
Cancer
|
|
Macropa-NH2 hydrochloride is the precursor of Macropa-NCS. Macropa-NCS is conjugated to Anti-Human HER2 (HY-P9907) as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases .
|
-
- HY-P99566
-
|
ST2146
|
Transmembrane Glycoprotein
|
Cancer
|
|
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .
|
-
- HY-P2112
-
|
DOTA-Nal3-octreotide
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Others
|
|
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-W717760
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-P10239
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10239A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10220
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Biochemical Assay Reagents
|
Others
|
|
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5128
-
|
Satoreotide tetraxetan
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-W782080
-
|
|
Biochemical Assay Reagents
|
Others
|
|
p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
|
-
- HY-P10307
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Bacterial
|
Infection
|
|
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158266
-
|
LNC1003
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-114133
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( 99mTc-depreotide) for optimal imaging properties. 99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5362
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-108694
-
|
|
Endogenous Metabolite
NF-κB
|
Metabolic Disease
Inflammation/Immunology
|
|
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .
|
-
- HY-P5297
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10369
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Betiatide, as a chelating agent for Technetium-99m ( 99mTc), is used to prepare 99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-164725
-
|
|
Radionuclide-Drug Conjugates (RDCs)
FAP
|
Cancer
|
|
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10741
-
-
- HY-P5362A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-D2363
-
|
|
FAP
Radionuclide-Drug Conjugates (RDCs)
Prolyl Endopeptidase (PREP)
|
Cancer
|
|
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5018
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Ser/Thr Protease
|
Cancer
|
|
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by 64Cu and 68Ga. 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-108694R
-
|
|
Endogenous Metabolite
NF-κB
|
Metabolic Disease
Inflammation/Immunology
|
|
γ-Tocotrienol (Standard) is the analytical standard of γ-Tocotrienol. This product is intended for research and analytical applications. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .
|
-
- HY-P5290
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158125
-
|
|
PSMA
|
Cancer
|
|
PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P5292
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10444
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10446
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Epigenetic Reader Domain
|
Cancer
|
|
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD4/JMJD6 and inhibit the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer . TAT-PiET-PROTAC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5292A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158123
-
|
|
PSMA
|
Cancer
|
|
PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with 225Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT) , has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P5520
-
|
|
Bombesin Receptor
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .
|
-
- HY-P5126
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158122
-
|
|
DNA-PK
|
Cancer
|
|
Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P5126A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158118
-
|
|
DNA-PK
|
Cancer
|
|
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-158067
-
|
DFO-DBCO
|
Chelators
|
|
Deferoxamine-DBCOis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative used for tumor pre-targeting. Deferoxamine-DBCO can be used for conjugation of peptides and radionuclides.
|
-
- HY-W088413
-
|
|
Chelators
|
|
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782078
-
|
|
Chelators
|
|
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W678394
-
|
|
Chelators
|
|
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.
|
-
- HY-W283556
-
|
|
Chelators
|
|
DO2A-tert-butyl ester is a bifunctional chelator (BFC) that can be used for the coupling of peptides and radionuclides. DO2A-tert-butyl ester can be used in the development of radionuclide imaging tracers .
|
-
- HY-138134
-
|
|
Chelators
|
|
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.
|
-
- HY-134418A
-
|
|
Chelators
|
|
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-138269A
-
|
CHX-A''-DTPA-NCS hydrochloride
|
Chelators
|
|
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-158072
-
|
|
Chelators
|
|
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717830
-
|
|
Chelators
|
|
CB-Cyclamis a bifunctional chelator (Bifunctional Chelator; BFC), which is a main chain Cyclen derivative of the macrocyclic ligand tetradecane. CB-Cyclam can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717743
-
|
|
Chelators
|
|
DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.
|
-
- HY-W726767
-
|
|
Chelators
|
|
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717782
-
|
|
Chelators
|
|
Bz-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Bz-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W087027A
-
|
|
Chelators
|
|
Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.
|
-
- HY-158077
-
|
(R)-tetraMe-DOTA
|
Chelators
|
|
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
|
-
- HY-W250844A
-
|
|
Chelators
|
|
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W539916
-
|
|
Chelators
|
|
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-128890A
-
|
|
Chelators
|
|
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717779
-
|
|
Chelators
|
|
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-A0074
-
|
tetra-tBu-DTPA
|
Chelators
|
|
DTPA-tetra (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. DTPA-tetra (t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717781A
-
|
|
Chelators
|
|
p-NH?-Bn-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782088A
-
|
|
Chelators
|
|
p-NH?-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782087A
-
|
|
Chelators
|
|
p-SCN-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-SCN-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782083
-
|
|
Chelators
|
|
p-SCN-Bn-NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-SCN-Bn-NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-156038
-
|
|
Chelators
|
|
(S)-p-SCN-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W749627
-
|
|
Chelators
|
|
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.
|
-
- HY-158068
-
|
|
Chelators
|
|
Maleimido-mono-amide-DTPA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DTPA (TFA) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W802013
-
|
|
Chelators
|
|
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.
|
-
- HY-131673A
-
|
|
Chelators
|
|
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W451440
-
|
|
Chelators
|
|
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717800A
-
|
|
Chelators
|
|
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-156138A
-
|
|
Chelators
|
|
CB-TE2A (tetrahydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC), which is a TETA derivative of the macrocyclic ligand tetradecane backbone. CB-TE2A (tetrahydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717833
-
|
|
Chelators
|
|
NO2A-(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717742
-
|
|
Chelators
|
|
p-NO2-Bn-Cyclenis a bifunctional chelator (Bifunctional Chelator; BFC), which is a derivative of the macrocyclic ligand dodecane backbone Cyclen. p-NO2-Bn-Cyclen can be used for conjugation of peptides and radionuclides.
|
-
- HY-48876
-
|
|
Chelators
|
|
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782075
-
|
|
Chelators
|
|
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-158066
-
|
|
Chelators
|
|
p-NH2-Bn-NOTA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-NH2-Bn-NOTA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.
|
-
- HY-158069
-
|
|
Chelators
|
|
p-NH?-Bn-DTPA-penta (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA-penta (t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W250929
-
|
|
Chelators
|
|
Maleimido-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W460274
-
|
|
Chelators
|
|
4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-148646A
-
|
|
Chelators
|
|
p-NH2-CHX-A"-DTPA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH2-CHX-A"-DTPA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W749614
-
|
|
Chelators
|
|
NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W749603
-
|
|
Chelators
|
|
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782081
-
|
|
Chelators
|
|
p-SCN-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-SCN-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717760
-
|
|
Chelators
|
|
p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782080
-
|
|
Chelators
|
|
p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-106033
-
|
DOTATOC; SDZ-SMT 487; SMT 487
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer . Edotreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-106244
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-106244A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P3441A
-
|
|
FAP
|
Cancer
|
|
3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 TFA is often coupled with radionuclides for tumor diagnosis and research .
|
-
- HY-P10131
-
|
|
Radionuclide-Drug Conjugates (RDCs)
FAP
|
Cancer
|
|
3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment . 3BP-3940 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P3441
-
|
|
FAP
|
Cancer
|
|
3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research .
|
-
- HY-P10743
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P2218
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10758
-
-
- HY-P10232
-
|
HYNIC-Tyr3-octreotide
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10761
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Carbonic Anhydrase
|
Cancer
|
|
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130?nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10781
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
PSMA-D5 has a binding affinity for PSMA with Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ 68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([ 68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10292
-
-
- HY-P10273
-
-
- HY-153549
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Others
|
|
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10744
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P3440
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PD-1/PD-L1
|
Cancer
|
|
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .
|
-
- HY-P10012
-
|
GYK-DTPA
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma . Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10273A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Biochemical Assay Reagents
|
Cancer
|
|
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-153550
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Others
|
|
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging . PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P2112
-
|
DOTA-Nal3-octreotide
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Others
|
|
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10239
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10239A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10220
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Biochemical Assay Reagents
|
Others
|
|
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5128
-
|
Satoreotide tetraxetan
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10307
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Bacterial
|
Infection
|
|
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-158266
-
|
LNC1003
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-114133
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( 99mTc-depreotide) for optimal imaging properties. 99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5362
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P5297
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-P10369
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Betiatide, as a chelating agent for Technetium-99m ( 99mTc), is used to prepare 99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-164725
-
|
|
Radionuclide-Drug Conjugates (RDCs)
FAP
|
Cancer
|
|
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10741
-
-
- HY-P5362A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
|
-
- HY-D2363
-
|
|
FAP
Radionuclide-Drug Conjugates (RDCs)
Prolyl Endopeptidase (PREP)
|
Cancer
|
|
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5018
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Ser/Thr Protease
|
Cancer
|
|
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by 64Cu and 68Ga. 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5290
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5292
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10444
-
|
|
Radionuclide-Drug Conjugates (RDCs)
CXCR
|
Cancer
|
|
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P10446
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Epigenetic Reader Domain
|
Cancer
|
|
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD4/JMJD6 and inhibit the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer . TAT-PiET-PROTAC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5292A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5520
-
|
|
Bombesin Receptor
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .
|
-
- HY-P5126
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-P5126A
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
|
Cancer
|
|
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99566
-
|
ST2146
|
Transmembrane Glycoprotein
|
Cancer
|
|
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-158067
-
|
DFO-DBCO
|
|
DBCO
|
|
Deferoxamine-DBCOis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative used for tumor pre-targeting. Deferoxamine-DBCO can be used for conjugation of peptides and radionuclides.
|
-
- HY-W782078
-
|
|
|
Alkynes
|
|
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W539916
-
|
|
|
Azide
|
|
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.
|
-
- HY-W749627
-
|
|
|
Alkynes
|
|
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.
|
-
- HY-P10758
-
|
|
|
Alkynes
|
|
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-W451440
-
|
|
|
Alkynes
|
|
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W717800A
-
|
|
|
Azide
|
|
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.
|
-
- HY-W749614
-
|
|
|
Alkynes
|
|
NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-160059
-
|
|
|
Aptamers
|
|
JHIT2e aptamer sodium is a molecular probe based on the aptamer JHIT2 of human liver cancer cell line HepG2 cells. JHIT2e aptamer sodiu retains the ability to specifically bind HepG2 and can deliver fluorescent materials or radionuclides to tumors .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
